Close

Drug Research

Cellectricon introduces Cellaxess discovery platform

Cellectricon has launched a new Cellaxess elektra discovery platform for automated electric field manipulation of adherent cells. Developed in collaboration with pharma and biotechnology companies, the Cellaxess platform enables scalable field stimulation, compound delivery...

Aegis wins US patent for octreotide formulations

Aegis Therapeutics has received US patent covering pharmaceutical composition of octreotide. The octreotide formulations incorporate Aegis' Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. The Intravail/ProTek...

Cellectis introduces human iPS derived hepatocyte product

Cellectis stem cells, a business unit of Cellectis Group, has introduced hiPS-HEP, a human iPS derived hepatocyte product. The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a...

Antares, Watson Pharmaceuticals launch Gelnique 3% in US

Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder. The product is available in a metered pump dispenser and is delivered transdermally, resulting in a...

Meridian, Teva settle epinephrine auto-injector pending patent litigation

Meridian Medical Technologies, a Pfizer subsidiary, and Teva have entered into a settlement agreement to resolve generic epinephrine auto-injector pending patent litigation. Under the terms of the agreement, Teva may launch a generic epinephrine...

Affymax, Takeda launch OMONTYS injection in US

Affymax and Takeda Pharmaceutical Company have announced the availability of OMONTYS injection to treat anemia due to chronic kidney disease (CKD) in adult patients on dialysis. The once-monthly erythropoiesis-stimulating agent (ESA) for anemia is...

Watson introduces generic version of Fortamet

Watson Pharmaceuticals has introduced an authorized generic version of Fortamet as a part of an agreement with Shionogi. The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read